The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study-Reference-Cited by-同舟云学术

The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study

Published:2021-12 Issue: Volume: Page:
ISSN:0929-6646
Container-title:Journal of the Formosan Medical Association
language:en
Short-container-title:Journal of the Formosan Medical Association

Author:

Kuo Chia-Jung,Le Puo-Hsien^ORCID,Tai Wei-Chen^ORCID,Wu Keng-Liang,Yen Hsu-Heng,Yen Chih-Wei,Tung Shui-Yi,Chung Chen-Shuan^ORCID,Su Ming-Yao,Chiu Cheng-Tang

Funder

Chang Gung Memorial Hospital Linkou Branch

Chang Gung Memorial Hospital

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Inflammatory bowel disease;Abraham;N Engl J Med,2009

2. Pathophysiology of inflammatory bowel diseases;Chang;N Engl J Med,2020

3. An update on the epidemiology of inflammatory bowel disease in Asia;Thia;Am J Gastroenterol,2008

4. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review;Molodecky;Gastroenterology,2012

5. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies;Ng;Lancet,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review;Journal of Managed Care & Specialty Pharmacy;2024-09

2. Real-life effectiveness and safety of vedolizumab in moderate-to-severe ulcerative colitis: A single-center experience in Northern China;Medicine;2024-07-05

3. Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study;Alimentary Pharmacology & Therapeutics;2024-04-14

4. Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis;Pharmacological Research;2024-04

5. Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China;Frontiers in Pharmacology;2023-05-04